posted
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
EPS: was 0.01 in 2005...NOW is 0.02
SIX MONTHS comparision
Six months ended June 30, 2006 2005
Net sales $ 13,143,595 $ 11,827,665 Cost of sales 8,234,032 8,116,059
Gross Profit 4,909,563 3,711,606
Also a little para from the SEC filing
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
-------------------- This is not a recommendation to buy or sell securities.
IP: Logged |
posted
Well the numbers got all mixed but the bottom line is year after year there has been steady growth...Thats why its better to get in now than later when everybody takes notice and it starts running up!!
Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
-------------------- This is not a recommendation to buy or sell securities.
IP: Logged |
posted
Comvita buys a stake in DSCI.....Finding international interest!!!
Saturday August 12, 2006 By Liam Dann
Honey and bee product company Comvita yesterday posted a mixed result for the six months to June 30. Net profits were down 7 per cent but overall sales were up 26 per cent.
Total revenue increased to $18.3 million from $14.5 million for the corresponding period last year. Net profit after tax was $602,000.
While that was lower than the half-year result of a year ago, it was well ahead of budget and in line with forecasts signalled at the AGM in April, the company said.
The Bay of Plenty-based firm sells a range of products, including honey, propolis, bee pollen, royal jelly and manuka honey wound-care products.
Chief executive Brett Hewlett said the most pleasing aspect of the result was that even with considerable investment being put into skilled staff and infrastructure for future growth, ebitda (earnings before interest, tax, depreciation and amortisation) had increased 15 per cent.
He said a return to strong sales in New Zealand, a rapidly growing Hong Kong market, heightened demand in the UK and steady growth in China and Australia had continued the 2005 pattern of sales growth for Comvita.
"Looking ahead, we expect sales growth to continue at the same rate as the first half of the year and the benefits of a lower currency starting to impact positively on our result.
"This impressive start to 2006 is evidence that our five-year growth strategy is well and truly on track."
The board has declared an interim dividend of 2c share. The company has purchased a strategic stake in US-based Derma Sciences, a specialist wound-care company. The shares closed steady at $3.56.
-------------------- This is not a recommendation to buy or sell securities.
IP: Logged |
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
-------------------- This is not a recommendation to buy or sell securities.
IP: Logged |
posted
I hope somebody listens to me here... Ask now is 78 cents... Lordy lordy lordy!!! Look at the financials I posted..This company would fly over next one year..... $500 thrown at this baby would only help ur portfolio!!!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
